我国药物滥用监测工作发展历程及现状

doi:10.19803/j.1672-8629.2020.11.06

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 777-779.
DOI: 10.19803/j.1672-8629.2020.11.06

我国药物滥用监测工作发展历程及现状

班炳坤¹, 任鹏宇², 韦敬土¹, 曹子菁¹

¹黔南州药品不良反应监测与评价中心,贵州都匀 558000;
²贵州省药品评价中心,贵州贵阳 550000

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
作者简介:班炳坤,女,硕士,副主任药师,药品不良反应监测与评价。

Course of Development and Status quo of Drug Abuse Monitoring in China

BAN bingkun¹, REN pengyu², WEI jingtu¹, CAO zijing¹

¹AADR Monitoring and Evaluation Center of Qiannan Prefecture, Duyun Guizhou 558000, China;
²Drug Evaluation Center of Guizhou Province, Guiyang Guizhou 550000, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的了解我国药物滥用监测工作的历史、现状及问题,为今后工作提供思路和方法。方法通过查阅文献,梳理我国药物滥用监测工作的发展历程,并分析工作进展、面临的困难及对策。结果我国药物滥用监测工作仍处于起步阶段,缺乏完整的法律法规体系、明确的组织机构框架及职能、工作协调机制、专业人才队伍及完善的药物滥用监测信息系统。结论亟需建立健全相关法律体系,明确机构和职能,完善监测模式,加强人员、经费保障等,稳定的多部门长效沟通协作机制,完善的药物滥用监测信息系统,加强宣传,营造社会共治的氛围。

关键词: 药物滥用, 监测, 发展历程, 现状

Abstract: Objective To investigate the history of and problems with drug abuse monitoring in China in order to offer new ideas for future work. Methods By reading literature, the course of development of drug abuse monitoring in China was reviewed, achievements summarized, while related difficulties, problems and countermeasures were presented. Results Drug abuse monitoring in China was still in infancy, without a complete legal and regulatory system, clear organizational framework and responsibilities, feasible inter-departmental coordination mechanism, professional talent team or perfect drug abuse monitoring information system. Conclusion It's urgent to establish and improve the related legal system, specify the organization and responsibilities, perfect the mode of monitoring, provide the personnel and expenses needed, establish a long-acting mechanism of communication and cooperation, improve the drug abuse monitoring information system, enhance publicity, and create an atmosphere of social co-governance.

Key words: drug abuse, monitoring, course of development, current situation

中图分类号:

R996.5

班炳坤, 任鹏宇, 韦敬土, 曹子菁. 我国药物滥用监测工作发展历程及现状[J]. 中国药物警戒, 2020, 17(11): 777-779.

BAN bingkun, REN pengyu, WEI jingtu, CAO zijing. Course of Development and Status quo of Drug Abuse Monitoring in China[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 777-779.

参考文献

[1] National Medical Products Administration. Annual National Drug Abuse Monitoring Report (China,2016) [EB/OL].(2017-08-11) [2020-01-07]. http://www.nmpa.gov.cn/WS04/CL2196/324182.html.
[2] National Center for ADR Monitoring,China. Compilation of regulatory documents on drug abuse monitoring(药物滥用监测工作法规文件汇编)[C]. Beijing: National Center for ADR Monitoring,China, 2018:1-111.
[3] Yi BL.Investigation and study of Sichuan province drug abuse monitoring present situation[D].Chengdu:University of Eelectronic Sscience and Ttechnology of China(电子科技大学),2015:1-16.
[4] Liu R, Liu YQ, Ding J et al. On modes of surveillance of drug abuse in three northern Chinese provinces[J]. Journal of Lanzhou University(Medical Sciences)(兰州大学学报),2018,44(2):23-27.
[5] The Sstate Ccouncil of China. The notice of the Sstate Ccouncil on the 13th five-year national food safety plan and the 13th five-year national drug safety plan[EB/OL]. (2017-02-21) [2020-01-07].http://www.gov.cn/zhengce/content/2017-02/21/content_5169755.htm.
[6] Wang KH, Wei Y, Xu YM et al. Current status of drug abuse epidemic and intervention research in Cchina[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(6):338-341.
[7] National Medical Products Administration. Annual National Drug Abuse Monitoring Report (China, 2014) [EB/OL].(2015-09-08) [2020-01-07]. http://www.nmpa.gov.cn/WS04/CL2168/329325.html.
[8] National Narcotics ControlBan Drugs Commission. Report on the drug situation in Cchina(2014) [R].Beijing: National Ban Drugs Commission,2015.
[9] National Narcotics ControlBan Drugs Commission. Report on the drug situation in Cchina(2015) [R].Beijing: National Ban Drugs Commission,2016.
[10] National Narcotics ControlBan Drugs Commission. Report on the drug situation in Cchina(2016) [R].Beijing: National Ban Drugs Commission,2017.
[11] Cong MC,Bao YP, LV XX et al.The research on the status of national drug abuse surveillance system[J].Chin J Drug Depend(中国药物依赖性杂志), 2013,22(5):386-393.
[12] Yan XS, Hong J, Zhu L.Analysis on the status quo and pProblems of drug abuse monitoring in Anhui Province[J]. Technology Wind(科技风), 2019(5) :212-213.
[13] Cong L, Guo YD, Sui XF.Discussion on the restraining factors influencing the further development of drug abuse monitoring[J]. Chinese Ppharmaceutical Aaffairs(中国药事), 2017,31(5) :463-466.
[14] Chen YF, Huang Y, Dong F et al. Cognitive investigation on drug abuse and drug abuse monitoring among Linyi medical staff. Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(9):541-544.
[15] Yang SL, Gu YQ, Liu ZX et al. The study on the prevalence of drug abuse and prevention for night clubs[J]. Chin J Drug Depend(中国药物依赖性杂志),2017,26(2):109-114.

我国药物滥用监测工作发展历程及现状

Course of Development and Status quo of Drug Abuse Monitoring in China

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.
[2]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[3]	邰隽, 于淼, 张琳, 雷毅, 刘军廷, 李涛, 黄贵民, 程毅菁, 聂晓璐, 王青. 基于自然语言处理技术的儿童病例注射用尖吻蝮蛇血凝酶不良反应主动监测方法构建与验证研究[J]. 中国药物警戒, 2023, 20(9): 1011-1016.
[4]	黄翠丽, 高奥, 王嘉熙, 郭海丽, 徐晓涵, 程吟楚, 郭代红. 抗菌药物相关血小板减少症的自动监测与评价研究[J]. 中国药物警戒, 2023, 20(7): 807-811.
[5]	刘芫汐, 辜冬琳, 汪祺, 姚令文, 王莹, 金红宇, 马双成. 液相色谱-串联质谱法测定何首乌中87种农药残留[J]. 中国药物警戒, 2023, 20(6): 601-608.
[6]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[7]	陈晨鑫, 张朋朋, 刘永梅, 叶小飞, 贺佳. 零膨胀模型与狄利克雷过程结合在药品上市后不良反应信号检测中的应用[J]. 中国药物警戒, 2023, 20(6): 651-654.
[8]	. 国家药品不良反应监测年度报告（2022年）[J]. 中国药物警戒, 2023, 20(6): 712-719.
[9]	赵燕, 刘文博, 赵一飞, 李栋, 郑立佳, 宋雅娜, 赵玉娟, 董放. 患者登记研究应用于医疗器械监管科学的实践研究与思考[J]. 中国药物警戒, 2023, 20(4): 423-427.
[10]	郑宇静, 赵紫楠, 金鹏飞, 赵飞, 胡欣, 张亚同. 基于医疗机构信息系统的卡培他滨致手足综合征不良反应主动监测[J]. 中国药物警戒, 2023, 20(4): 441-443.
[11]	王嘉熙, 郭代红, 张博, 李伯妍, 郭海丽. 116097例氟比洛芬酯用药人群的急性肾损伤自动监测研究及危险因素分析[J]. 中国药物警戒, 2023, 20(2): 201-205.
[12]	赵燕, 李栋, 程音婕, 江滨, 赵一飞, 董放, 袁静. 医疗器械上市后安全性数据来源和信号识别方法研究进展[J]. 中国药物警戒, 2023, 20(2): 236-240.
[13]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[14]	赵燕, 李尧, 宋雅娜, 郑立佳, 李栋, 赵一飞, 卞蓉蓉, 董放. 警戒视域下开展医疗器械上市后主动监测的实践研究与思考[J]. 中国药物警戒, 2023, 20(12): 1385-1390.
[15]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.